BVXV Annual EBIT
-$11.06 M
-$199.00 K-1.83%
31 December 2022
Summary:
As of February 5, 2025, BVXV annual earnings before interest & taxes is -$11.06 million, with the most recent change of -$199.00 thousand (-1.83%) on December 31, 2022. During the last 3 years, it has risen by +$16.16 million (+59.37%).BVXV EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BVXV Quarterly EBIT
-$2.60 M
+$591.00 K+18.55%
30 June 2023
Summary:
As of February 5, 2025, BVXV quarterly earnings before interest & taxes is -$2.60 million, with the most recent change of +$591.00 thousand (+18.55%) on June 30, 2023. Over the past year, it has increased by +$668.00 thousand (+20.47%).BVXV Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BVXV TTM EBIT
-$12.27 M
+$668.00 K+5.16%
30 June 2023
Summary:
As of February 5, 2025, BVXV TTM earnings before interest & taxes is -$12.27 million, with the most recent change of +$668.00 thousand (+5.16%) on June 30, 2023. Over the past year, it has dropped by -$141.50 thousand (-1.17%).BVXV TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BVXV EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -1.8% | +20.5% | -1.2% |
| 3 y3 years | +59.4% | +44.4% | +51.3% |
| 5 y5 years | -11.3% | +60.9% | +49.5% |
BVXV EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | +3864.5% | -116.1% | -442.9% |
BiondVax Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | -$2.60 M(-18.5%) | -$12.27 M(-5.2%) |
| Mar 2023 | - | -$3.19 M(-65.6%) | -$12.94 M(+4.6%) |
| Dec 2022 | -$11.06 M(+1.8%) | -$9.27 M(-433.5%) | -$12.37 M(+66.9%) |
| Sept 2022 | - | $2.78 M(-185.2%) | -$7.41 M(-38.9%) |
| June 2022 | - | -$3.26 M(+24.8%) | -$12.13 M(+4.6%) |
| Mar 2022 | - | -$2.62 M(-39.4%) | -$11.60 M(+8.9%) |
| Dec 2021 | -$10.86 M(+947.9%) | -$4.31 M(+122.5%) | -$10.66 M(-26.4%) |
| Sept 2021 | - | -$1.94 M(-29.1%) | -$14.48 M(-504.6%) |
| June 2021 | - | -$2.73 M(+63.8%) | $3.58 M(+117.3%) |
| Mar 2021 | - | -$1.67 M(-79.5%) | $1.65 M(-29.1%) |
| Dec 2020 | -$1.04 M(-96.2%) | -$8.14 M(-150.5%) | $2.32 M(-163.2%) |
| Sept 2020 | - | $16.12 M(-445.5%) | -$3.67 M(-85.4%) |
| June 2020 | - | -$4.67 M(+369.8%) | -$25.18 M(-3.2%) |
| Mar 2020 | - | -$993.40 K(-93.0%) | -$26.03 M(+7.0%) |
| Dec 2019 | -$27.23 M(+38.2%) | -$14.14 M(+162.6%) | -$24.32 M(+28.0%) |
| Sept 2019 | - | -$5.38 M(-2.3%) | -$19.00 M(+33.8%) |
| June 2019 | - | -$5.51 M(-872.1%) | -$14.20 M(-7.3%) |
| Mar 2019 | - | $713.60 K(-108.1%) | -$15.32 M(-22.0%) |
| Dec 2018 | -$19.70 M | -$8.82 M(+1422.7%) | -$19.63 M(+7.4%) |
| Sept 2018 | - | -$579.40 K(-91.3%) | -$18.27 M(+5.6%) |
| June 2018 | - | -$6.63 M(+84.4%) | -$17.31 M(+51.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | -$3.60 M(-51.8%) | -$11.42 M(+32.2%) |
| Dec 2017 | -$9.94 M(+316.4%) | -$7.46 M(-2053.8%) | -$8.64 M(+355.2%) |
| Sept 2017 | - | $381.90 K(-151.5%) | -$1.90 M(-32.9%) |
| June 2017 | - | -$741.50 K(-9.2%) | -$2.83 M(+2.4%) |
| Mar 2017 | - | -$816.90 K(+13.3%) | -$2.76 M(+19.9%) |
| Dec 2016 | -$2.39 M(-17.5%) | -$721.30 K(+31.1%) | -$2.31 M(-15.3%) |
| Sept 2016 | - | -$550.00 K(-18.7%) | -$2.72 M(+27.4%) |
| June 2016 | - | -$676.40 K(+89.0%) | -$2.14 M(-7.5%) |
| Mar 2016 | - | -$357.90 K(-68.5%) | -$2.31 M(-4.2%) |
| Dec 2015 | -$2.90 M(+38.5%) | -$1.14 M(-3309.9%) | -$2.41 M(+38.3%) |
| Sept 2015 | - | $35.40 K(-104.2%) | -$1.74 M(-23.1%) |
| June 2015 | - | -$849.30 K(+85.0%) | -$2.26 M(+10.8%) |
| Mar 2015 | - | -$459.20 K(-2.1%) | -$2.04 M(-4.7%) |
| Dec 2014 | -$2.09 M(-4.7%) | -$468.90 K(-3.7%) | -$2.15 M(-4.1%) |
| Sept 2014 | - | -$486.80 K(-22.7%) | -$2.24 M(-2.5%) |
| June 2014 | - | -$629.50 K(+12.4%) | -$2.30 M(+37.8%) |
| Mar 2014 | - | -$560.30 K(-0.2%) | -$1.67 M(+50.7%) |
| Dec 2013 | -$2.19 M(-10.3%) | -$561.50 K(+3.2%) | -$1.11 M(+103.2%) |
| Sept 2013 | - | -$544.00 K | -$544.00 K |
| Dec 2012 | -$2.44 M(+13.1%) | - | - |
| Dec 2011 | -$2.16 M | - | - |
FAQ
- What is BiondVax Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for BiondVax Pharmaceuticals?
- What is BiondVax Pharmaceuticals annual EBIT year-on-year change?
- What is BiondVax Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for BiondVax Pharmaceuticals?
- What is BiondVax Pharmaceuticals quarterly EBIT year-on-year change?
- What is BiondVax Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for BiondVax Pharmaceuticals?
- What is BiondVax Pharmaceuticals TTM EBIT year-on-year change?
What is BiondVax Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of BVXV is -$11.06 M
What is the all time high annual EBIT for BiondVax Pharmaceuticals?
BiondVax Pharmaceuticals all-time high annual earnings before interest & taxes is -$279.00 K
What is BiondVax Pharmaceuticals annual EBIT year-on-year change?
Over the past year, BVXV annual earnings before interest & taxes has changed by -$199.00 K (-1.83%)
What is BiondVax Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of BVXV is -$2.60 M
What is the all time high quarterly EBIT for BiondVax Pharmaceuticals?
BiondVax Pharmaceuticals all-time high quarterly earnings before interest & taxes is $16.12 M
What is BiondVax Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, BVXV quarterly earnings before interest & taxes has changed by +$668.00 K (+20.47%)
What is BiondVax Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of BVXV is -$12.27 M
What is the all time high TTM EBIT for BiondVax Pharmaceuticals?
BiondVax Pharmaceuticals all-time high TTM earnings before interest & taxes is $3.58 M
What is BiondVax Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, BVXV TTM earnings before interest & taxes has changed by -$141.50 K (-1.17%)